StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on the stock. JMP Securities reiterated a “market outperform” rating and set a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st. Oppenheimer cut their price target on shares of Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 12th.

Cellectis Trading Up 3.5 %

NASDAQ:CLLS opened at $1.94 on Friday. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77. The stock has a market cap of $107.55 million, a P/E ratio of -1.50 and a beta of 3.11. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.63 and a current ratio of 1.63. The stock has a 50-day simple moving average of $2.59 and a 200-day simple moving average of $2.74.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The business had revenue of $6.50 million during the quarter. As a group, analysts anticipate that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. boosted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the period. Principal Financial Group Inc. owned approximately 0.76% of Cellectis worth $1,125,000 as of its most recent filing with the SEC. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.